RxDoctor Payments Data

Jasen Kobobel, MD

Family Medicine · Rockledge, FLNPI 1073550950

Payments from drug & device makers

$4,756in general payments, 2019–2025

Across 258 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$301
  • Novo Nordisk$200
  • Exact Sciences$155
  • Amgen$145
  • GSK$142
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,736100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,756 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$332,374
Medicare patients
616
Services billed
4,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$46,718
EliquisApixaban37$44,241
FarxigaDapagliflozin Propanediol32$29,484
Repatha SureclickEvolocumab27$23,171
MounjaroTirzepatide12$16,090
XareltoRivaroxaban13$9,610
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$8,748
Praluent PenAlirocumab13$6,774
SynthroidLevothyroxine Sodium41$4,353
Nebivolol Hcl85$3,806
Testosterone23$3,743
Ezetimibe64$2,641
Wixela InhubFluticasone Propion/Salmeterol12$2,507
Levothyroxine Sodium181$2,422
Dutasteride78$2,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$200$46,71840 claims
PfizerEliquis$70$44,24137 claims
AstraZenecaFarxiga$301$29,48432 claims
Lilly USA, LLCMounjaro$87$16,09012 claims
Johnson & JohnsonXarelto$130$9,61013 claims
AbbVieSynthroid$2,665$4,35341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →